Zogenix, Inc. to Present Additional SUMAVEL(R) DosePro(R) Phase 4 Results at Headache Meetings in June

SAN DIEGO, May 27, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that additional data from the Company’s Phase 4 clinical study of SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System will be presented at two upcoming scientific meetings: the American Headache Society® 53rd Annual Scientific Meeting (AHS), to be held June 2 – 5, 2011 in Washington, DC; and the 15th Congress of the International Headache Society (IHS), to be held June 23 – 26, 2011 in Berlin, Germany.